Published online Jul 16, 2014. doi: 10.12998/wjcc.v2.i7.250
Revised: May 2, 2014
Accepted: June 10, 2014
Published online: July 16, 2014
Processing time: 106 Days and 17.4 Hours
A number of animal and human studies suggest omega 3-fatty acids are anti-inflammatory. As a result they may have a therapeutic role in inflammatory bowel disease (IBD). The aim of this review is to briefly assess the literature about the utility of poly-unsaturated fatty acids (PUFAs) in the management of IBD. Taken together, almost all studies suggest some beneficial effects of n-3 PUFAs in IBD but the mechanism remains controversial. In addition, clinical benefit seems to be largely confined to ulcerative colitis. However all studies have concluded that these compounds have no potential for a steroid/aminosalicylic acid sparing effect or to maintain remission. Now the question arises as to whether this treatment is of real value to IBD patients? Clearly they have some therapeutic potential but further work is needed.
Core tip: Fish oil supplements are probably of benefit to patients with ulcerative colitis. They have a much less certain role in Crohn’s disease.